Oragenics completes nasal device formulation for concussion drug ONP-002 ahead of Phase 2a trial.
Oragenics Inc., a biotech company, has finished spray-dried formulation and filling of its nasal device for its lead candidate ONP-002, targeting concussions. The prefilled formulation is for the upcoming Phase 2a clinical trial enrolling 40 concussed patients, with 1:1 placebo or ONP-002 drug given twice daily for five days following injury. The trial aims to start treatment within 8 hours of injury and includes patient-reported outcomes and blood biomarkers in evaluation.
August 21, 2024
5 Articles